Applied Biology, Inc.
26
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
26.9%
7 terminated/withdrawn out of 26 trials
56.3%
-30.3% vs industry average
35%
9 trials in Phase 3/4
67%
6 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Role: lead
Pharmacokinetic Study of DA-020
Role: lead
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Role: lead
Pharmacokinetic Study of Topical Phenylephrine
Role: lead
Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)
Role: lead
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Role: lead
Clinical Study of CS-001 As a Treatment for Canities (Grey Hair)
Role: lead
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
Role: lead
Clinical Study of Probiotic Treatment for Androgenetic Alopecia
Role: lead
COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression
Role: collaborator
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002
Role: lead
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
Role: lead
Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis
Role: lead
Treatment for Post Acute COVID-19 Syndrome
Role: lead
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
Role: lead
Proxalutamide Treatment for COVID-19 Female Outpatients
Role: lead
HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
Role: lead
Anti-Androgen Treatment for COVID-19
Role: lead
HairDx Analytical Validation Study
Role: lead
Proxalutamide Treatment for Hospitalized COVID-19 Patients
Role: lead